Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
A Stock Forecast 2026-2027
$111.51
Current Price
$31.57B
Market Cap
Buy 15
Hold 5
Sell 0
Wall St Analyst Ratings
Distance to A Price Targets
+65.9%
To High Target of $185.00
+43.5%
To Median Target of $160.00
+34.5%
To Low Target of $150.00
A Price Momentum
-3.1%
1 Week Change
-11.4%
1 Month Change
-8.0%
1 Year Change
-18.0%
Year-to-Date Change
-30.4%
From 52W High of $160.27
+15.6%
From 52W Low of $96.43
📊 TOP ANALYST CALLS
Did A Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Agilent is one of their latest high-conviction picks.
Latest A Stock Price Targets & Analyst Predictions
Based on our analysis of 29 Wall Street analysts, A has a bullish consensus with a median price target of $160.00 (ranging from $150.00 to $185.00). The overall analyst rating is Strong Buy (8.6/10). Currently trading at $111.51, the median forecast implies a 43.5% upside. This outlook is supported by 15 Buy, 5 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Patrick Donnelly at Citigroup, projecting a 65.9% upside. Conversely, the most conservative target is provided by Luke Sergott at Barclays, suggesting a 34.5% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
A Analyst Ratings
15
Buy
5
Hold
0
Sell
A Price Target Range
Low
$150.00
Average
$160.00
High
$185.00
Current: $111.51
Latest A Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for A.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 3, 2026 | Morgan Stanley | Kallum Titchmarsh | Overweight | Maintains | $160.00 |
| Feb 26, 2026 | Wells Fargo | Brandon Couillard | Overweight | Maintains | $165.00 |
| Feb 26, 2026 | Barclays | Luke Sergott | Overweight | Maintains | $150.00 |
| Feb 26, 2026 | TD Cowen | Dan Brennan | Buy | Maintains | $157.00 |
| Feb 26, 2026 | UBS | Dan Leonard | Buy | Maintains | $165.00 |
| Jan 20, 2026 | HSBC | Sidharth Sahoo | Buy | Initiates | $180.00 |
| Jan 5, 2026 | Evercore ISI Group | Vijay Kumar | Outperform | Upgrade | $160.00 |
| Dec 15, 2025 | Barclays | Luke Sergott | Overweight | Upgrade | $165.00 |
| Dec 9, 2025 | Goldman Sachs | Evie Koslosky | Buy | Initiates | $170.00 |
| Dec 2, 2025 | Morgan Stanley | Kallum Titchmarsh | Overweight | Initiates | $180.00 |
| Nov 25, 2025 | Barclays | Luke Sergott | Equal-Weight | Maintains | $165.00 |
| Nov 25, 2025 | UBS | Dan Leonard | Buy | Maintains | $180.00 |
| Nov 25, 2025 | Wells Fargo | Brandon Couillard | Overweight | Maintains | $175.00 |
| Nov 25, 2025 | JP Morgan | Casey Woodring | Overweight | Maintains | $180.00 |
| Nov 25, 2025 | Citigroup | Patrick Donnelly | Buy | Maintains | $185.00 |
| Nov 25, 2025 | B of A Securities | Derik De Bruin | Neutral | Maintains | $165.00 |
| Nov 25, 2025 | Baird | Catherine Schulte | Outperform | Maintains | $165.00 |
| Oct 14, 2025 | TD Cowen | Dan Brennan | Buy | Maintains | $162.00 |
| Oct 9, 2025 | JP Morgan | Casey Woodring | Overweight | Maintains | $165.00 |
| Oct 8, 2025 | UBS | Dan Leonard | Buy | Upgrade | $170.00 |
Agilent Technologies Inc. (A) Competitors
The following stocks are similar to Agilent based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Agilent Technologies Inc. (A) Financial Data
Agilent Technologies Inc. has a market capitalization of $31.57B with a P/E ratio of 25.5x. The company generates $7.06B in trailing twelve-month revenue with a 18.3% profit margin.
Revenue growth is +7.0% quarter-over-quarter, while maintaining an operating margin of +22.9% and return on equity of +19.9%.
Valuation Metrics
Market Cap
$31.57B
Enterprise Value
$34.41B
P/E Ratio
25.5x
PEG Ratio
-7.1x
Price/Sales
4.6x
Growth & Margins
Revenue Growth (YoY)
+7.0%
Gross Margin
+52.6%
Operating Margin
+22.9%
Net Margin
+18.3%
EPS Growth
-4.1%
Financial Health
Cash/Price Ratio
+5.6%
Current Ratio
2.1x
Debt/Equity
51.4x
ROE
+19.9%
ROA
+8.5%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Agilent Technologies Inc. (A) Business Model
About Agilent Technologies Inc.
What They Do
Provides solutions for life sciences and diagnostics.
Business Model
The company operates through three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. It generates revenue by offering a range of instruments, software, and services tailored to research and diagnostic applications, including reagents and operational support to enhance laboratory performance.
Additional Information
Founded in 1999 and headquartered in Santa Clara, California, Agilent Technologies plays a crucial role in scientific advancements across multiple sectors, including pharmaceuticals, biotechnology, and environmental testing, with notable innovations like liquid chromatography systems and mass spectrometry.
Company Information
Sector
Healthcare
Industry
Diagnostics & Research
Employees
18,000
CEO
Mr. Padraig McDonnell
Country
United States
IPO Year
1999
Website
www.agilent.comAgilent Technologies Inc. (A) Latest News & Analysis
Latest News
Quick Summary
Citi initiated a 90-day upside catalyst watch on Agilent Technologies (NYSE:A) and reduced its price target on Icon PLC (NASDAQ:ICLR) after a challenging earnings season for life sciences.
Why It Matters
Citi's actions signal potential growth for Agilent Technologies, while a lowered price target for Icon PLC suggests caution. This affects investor sentiment and stock valuations in the sector.
Source: 24/7 Wall Street
Market Sentiment:
Positive
Quick Summary
Agilent Technologies (NYSE: A) launched Agilent Advanced Therapeutics, a unified CDMO solution, enhancing its manufacturing capabilities in Canada and the U.S. through BIOVECTRA and Nucleic Acid Solutions.
Why It Matters
Agilent Technologies’ launch of Advanced Therapeutics enhances its CDMO capabilities, potentially increasing revenue streams and market share in the growing biomanufacturing sector.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Agilent Technologies will acquire Biocare Medical for $950 million in an all-cash deal, enhancing its position in the life sciences sector.
Why It Matters
Agilent's $950 million acquisition of Biocare Medical enhances its portfolio in clinical pathology, potentially driving growth and market share in the life sciences sector.
Source: Reuters
Market Sentiment:
Positive
Agilent to Acquire Biocare Medical, a Global Leader in Clinical and Research Pathology Solutions
5 days ago
Quick Summary
Agilent Technologies Inc. (NYSE: A) has agreed to acquire Biocare Medical for $950 million in cash. Biocare is a leader in clinical pathology and immunohistochemistry.
Why It Matters
Agilent's acquisition of Biocare Medical for $950 million expands its portfolio in the growing pathology market, potentially enhancing revenue and market share, which can positively impact stock performance.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Biocare Medical has agreed to be acquired by Agilent Technologies. The deal involves Excellere Partners and GHO Capital, focusing on advancements in life sciences and diagnostics.
Why It Matters
Agilent's acquisition of Biocare enhances its portfolio in life sciences and diagnostics, potentially increasing revenue and market share, which can positively influence stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Agilent's reliance on international revenue is key to assessing its financial stability, growth potential, and stock price performance. Investors should analyze this aspect for informed decision-making.
Why It Matters
Agilent's reliance on international revenue impacts its financial stability and growth potential. Economic fluctuations abroad can affect earnings, influencing stock price performance.
Source: Zacks Investment Research
Market Sentiment:
Positive
Frequently Asked Questions About A Stock
What is Agilent Technologies Inc.'s (A) stock forecast for 2026?
Based on our analysis of 29 Wall Street analysts, Agilent Technologies Inc. (A) has a median price target of $160.00. The highest price target is $185.00 and the lowest is $150.00.
Is A stock a good investment in 2026?
According to current analyst ratings, A has 15 Buy ratings, 5 Hold ratings, and 0 Sell ratings. The stock is currently trading at $111.51. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for A stock?
Wall Street analysts predict A stock could reach $160.00 in the next 12 months. This represents a 43.5% increase from the current price of $111.51. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Agilent Technologies Inc.'s business model?
The company operates through three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. It generates revenue by offering a range of instruments, software, and services tailored to research and diagnostic applications, including reagents and operational support to enhance laboratory performance.
What is the highest forecasted price for A Agilent Technologies Inc.?
The highest price target for A is $185.00 from Patrick Donnelly at Citigroup, which represents a 65.9% increase from the current price of $111.51.
What is the lowest forecasted price for A Agilent Technologies Inc.?
The lowest price target for A is $150.00 from Luke Sergott at Barclays, which represents a 34.5% increase from the current price of $111.51.
What is the overall A consensus from analysts for Agilent Technologies Inc.?
The overall analyst consensus for A is bullish. Out of 29 Wall Street analysts, 15 rate it as Buy, 5 as Hold, and 0 as Sell, with a median price target of $160.00.
How accurate are A stock price projections?
Stock price projections, including those for Agilent Technologies Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: March 14, 2026 2:00 AM UTC